Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Medical Devices & Diagnostics
Medical Devices & Diagnostics
How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026
Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.
Medical Devices & Diagnostics
Exact Sciences unveils key Oncodetect results in TNBC: Is this a reimbursement turning point?
Exact Sciences Corporation has presented first-time clinical results for its Oncodetect molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC), showcasing a strong correlation between circulating tumor DNA (ctDNA) detection and recurrence risk following neoadjuvant therapy and surgery. The results, drawn from a 147-patient cohort in the NSABP B-59 substudy, were unveiled at